17
Nov
Objective to investigate whether a des can reduce the risk of. Objective to investigate whether a des can reduce the risk of.
Although dual antiplatelet therapy (dapt) beyond one year provides ischemic event protection following des, ischemic event risk is perceived to be less following bms and the.
Bare metal stent vs drug eluting stent. The composite endpoint of death, myocardial infarction, or target lesion revascularization is represented as a function of time and favors des. Patients who received at least one des (n = 4754) were compared with those who received only bare metal stents (bms) (n = 4956) at the index procedure. Furthermore, concerns have been raised on the higher risk of stent thrombosis after des implantation.
They may, however, be more prone than bare metal stents to late (beyond 1 year) and sudden coronary artery occlusion. However, there is a lack of evidence to support these recommendations. The summary risk differences excluded any major differences between the 2 types of stents for death (0.12%, 95% confidence interval [ci] −0.34% to 0.58%, p = 0.60) and.
Although dual antiplatelet therapy (dapt) beyond one year provides ischemic event protection following des, ischemic event risk is perceived to be less following bms and the. The randomised pepcad nstemi trial eurointervention. Combined outcome of death or myocardial infarction (mi) showed no difference for des vs.
Data sources and study selection pubmed, embase, and central were searched for. This difference was still present 3 years after stenting. Indeed, des are more expensive than bms.
Background while a growing number of reports offer evidence for the potential of drug eluting stents (des) in treating atherosclerotic stenosis of the extracranial vertebral artery, their efficacy when compared with bare metal stents (bms) is uncertain due to the lack of a large prospective randomized trial. Current expert consensus recommends the use of bare metal stent (bms) for patients with an indication for oral anticoagulation (oac) undergoing coronary stenting. Objective to compare the efficacy and safety of biodegradable polymer drug eluting stents with those of bare metal stents and durable polymer drug eluting stents.
Objective to investigate whether a des can reduce the risk of.